...
首页> 外文期刊>The Journal of Nuclear Medicine >Semiquantitative I-123-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters
【24h】

Semiquantitative I-123-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters

机译:半定量I-123-甲酰胺基苄基胍显像从生理性肾上腺摄取区分嗜铬细胞瘤和副神经节瘤及其与儿茶酚胺转运蛋白的基因型依赖性表达的相关性

获取原文
获取原文并翻译 | 示例
           

摘要

I-123-metaiodobenzylguanidine (I-123-MIBG) scintigraphy plays an important role in the diagnostic evaluation of patients with pheochromocytoma and paraganglioma (PPGL). I-123-MIBG targets cell membrane and vesicular catecholamine transporters of chromaffin cells and facilitates localization of the primary tumor and metastatic lesions. Its specificity for the diagnosis of adrenomedullary chromaffin cell tumors can be jeopardized by physiologic uptake by the normal adrenal medulla. The aim of this study was to distinguish between PPGLs and normal adrenal glands by evaluating semiquantitative I-123-MIBG uptake and to examine genotype-specific differences in correlation with expression of catecholamine transporter systems. Methods: Sixty-two PPGLs collected from 57 patients with hereditary mutations in SDHA (n = 1), SDHB (n = 2), and SDHD (n = 4) (SDH is succinate dehydrogenase); von Hippel-Lindau (VHL; n = 2); RET (n = 12); neurofibromin 1 (NF1; n = 2); and MYC-associated factor X (MAX; n = 1), and with sporadic PPGLs (n = 33) were investigated. Preoperative planar and SPECT images were semi-quantitatively analyzed using uptake measurements. Tumor-to-liver and normal adrenal-to-liver ratios were calculated and correlated with clinical characteristics including genotype, tumor size, and plasma metanephrines concentrations. The expression of norepinephrine transporter (NET) and vesicular monoamine transporter (VMAT-1) was evaluated immunohistochemically in paraffin-embedded tumor tissues. Results: Mean tumor-to-liver ratios of PPGL lesions were significantly higher than normal adrenal-to-liver ratios (P < 0.001). Cutoff values to distinguish between physiologic and pathologic adrenal uptake were established at 0.7 (100% sensitivity, 10.3% specificity) and 4.3 (100% specificity, 66.1% sensitivity). No statistically significant differences in I-123-MIBG uptake were found across PPGLs of different genotypes. Mean NET expression in hereditary cluster 2 (RET, NF1, MAX) and apparently sporadic tumors was significantly higher than for hereditary cluster 1 (SDHx, VHL) PPGLs (P = 0.011 and 0.006, respectively). Mean VMAT-1 expression in hereditary cluster 1 PPGLs was significantly higher than for cluster 2 tumors (P = 0.010). I-123-MIBG uptake significantly correlated with maximum tumor diameter (P = 0.002). I-123-MIBG uptake, however, did not correlate with either NET or VMAT-1 expression. Conclusion: Liver-normalized semiquantitative I-123-MIBG uptake may be helpful to distinguish between pheochromocytoma and physiologic adrenal uptake. Genotype-specific differences in the expression of NET and VMAT-1 do not translate into differences in I-123-MIBG uptake.
机译:I-123-蛋氨酸苄基胍(I-123-MIBG)闪烁显像在嗜铬细胞瘤和副神经节瘤(PPGL)患者的诊断评估中起着重要作用。 I-123-MIBG靶向嗜铬细胞的细胞膜和囊泡儿茶酚胺转运蛋白,并有助于原发肿瘤和转移性病变的定位。正常肾上腺髓质的生理摄取可能会损害其诊断肾上腺髓质嗜铬细胞瘤的特异性。这项研究的目的是通过评估半定量I-123-MIBG摄取来区分PPGL和正常肾上腺,并检查与儿茶酚胺转运蛋白系统表达相关的基因型特异性差异。方法:从57例SDHA(n = 1),SDHB(n = 2)和SDHD(n = 4)(SDH为琥珀酸脱氢酶)遗传性突变的患者中收集了62种PPGL。 von Hippel-Lindau(VHL; n = 2); RET(n = 12);神经纤维蛋白1(NF1; n = 2);和MYC相关因子X(MAX; n = 1)以及散发的PPGL(n = 33)进行了研究。术前平面图像和SPECT图像使用摄取测量值进行半定量分析。计算肿瘤与肝脏和正常肾上腺与肝脏的比率,并将其与临床特征相关,包括基因型,肿瘤大小和血浆中肾上腺素浓度。免疫组化法检测石蜡包埋的肿瘤组织中去甲肾上腺素转运蛋白(NET)和囊泡单胺转运蛋白(VMAT-1)的表达。结果:PPGL病变的平均肝肿瘤比率明显高于正常肾上腺肝比率(P <0.001)。区分生理性和病理性肾上腺摄取的截断值被确定为0.7(敏感性100%,特异性10.3%)和4.3(特异性100%,敏感性66.1%)。在不同基因型的PPGL之间,在I-123-MIBG摄取方面没有统计学上的显着差异。遗传簇2(RET,NF1,MAX)和明显散发性肿瘤中的平均NET表达显着高于遗传簇1(SDHx,VHL)PPGL(分别为P = 0.011和0.006)。遗传性聚类1 PPGLs中的平均VMAT-1表达明显高于聚类2肿瘤(P = 0.010)。 I-123-MIBG的摄取与最大肿瘤直径显着相关(P = 0.002)。但是,I-123-MIBG的摄取与NET或VMAT-1表达均不相关。结论:肝脏归一化半定量I-123-MIBG摄取可能有助于区分嗜铬细胞瘤和生理性肾上腺摄取。 NET和VMAT-1表达的基因型特异性差异不会转化为I-123-MIBG摄取差异。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号